Clinical

Dataset Information

0

Sequential and Concurrent FOLFOXIRI/Bevacizumab Regimens Versus FOLFOX/Bevacizumab in First-Line Metastatic Colorectal Cancer


ABSTRACT: This randomized, open-label, multicenter study will evaluate the efficacy and safety of folinic acid (leucovorin), 5-fluorouracil (5-FU), oxaliplatin, and irinotecan (FOLFOXIRI) / bevacizumab regimens (concurrent and sequential) versus folinic acid (leucovorin), 5-fluorouracil, and oxaliplatin (FOLFOX) / bevacizumab in first-line in participants with metastatic colorectal cancer. Participants will be randomized to receive bevacizumab 5 milligrams per kilogram (mg/kg) intravenously every 2 weeks with either concurrent or sequential FOLFOXIRI or with FOLFOX for 4 to 6 months of induction therapy, followed by maintenance therapy with bevacizumab plus either leucovorin/5-fluorouracil or capecitabine until disease progression occurs. After disease progression, participants will receive treatment with a fluoropyrimidine-based chemotherapy plus bevacizumab.

DISEASE(S): Colorectal Neoplasms

PROVIDER: 2138080 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2020-01-28 | GSE138912 | GEO
| 2078718 | ecrin-mdr-crc
| 2052240 | ecrin-mdr-crc
2011-03-25 | GSE21228 | GEO
| 2045850 | ecrin-mdr-crc
| 2163812 | ecrin-mdr-crc
2023-07-20 | GSE232525 | GEO
| 2110178 | ecrin-mdr-crc
2024-05-21 | PXD044201 | Pride
| 115222 | ecrin-mdr-crc